Private Capital Group’s NovoCure NVCR Stock Holding History

Private Capital Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$8K	Sell	108 -349	-76%	-$26.3K	0.01%	1123
2022 Q1	$38K	Buy	457 +44	+11%	+$3.24K	0.01%	750
2021 Q4	$31K	Sell	413 -68	-14%	-$6.83K	0.01%	880
2021 Q3	$56K	Buy	481 +23	+5%	+$3.48K	0.01%	627
2021 Q2	$102K	Sell	458 -410	-47%	-$79.8K	0.02%	410
2021 Q1	$115K	Sell	868 -139	-14%	-$22K	0.03%	350
2020 Q4	$174K	Buy	1,007 +33	+3%	+$4.52K	0.03%	342
2020 Q3	$108K	Buy	974 +51	+6%	+$4.08K	0.02%	427
2020 Q2	$55K	Sell	923 -20	-2%	-$1.31K	0.01%	666
2020 Q1	$64K	Buy	943 +76	+9%	+$6.01K	0.02%	545
2019 Q4	$73K	Buy	867 +54	+7%	+$4.36K	0.02%	562
2019 Q3	$61K	Hold	813	–	–	0.01%	678
2019 Q2	$25K	Hold	813	–	–	0.01%	973
2019 Q1	$39K	Hold	813	–	–	0.01%	896
2018 Q4	$27K	Hold	813	–	–	0.01%	963
2018 Q3	$42K	Hold	813	–	–	0.01%	795
2018 Q2	$25K	Hold	813	–	–	0.01%	1012
2018 Q1	$18K	Hold	813	–	–	﹤0.01%	1121
2017 Q4	$16K	Buy	+813	New	+$15.7K	﹤0.01%	1167

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Capital Group's NVCR Position: Q2 2022 in Review

Private Capital Group reduced its NovoCure (NVCR) stake by 76% in Q2 2022, selling an estimated $26.3K and leaving 108 shares worth $8K. The position accounts for 0.01% of the portfolio, ranked #1123.

Private Capital Group first reported a position in NVCR in Q4 2017 and has held it in 19 quarters since. The position peaked at $174K in Q4 2020. 317 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Private Capital Group held 108 shares of NovoCure worth $8K as of Q2 2022.
Private Capital Group sold 349 NovoCure shares in Q2 2022, an estimated $26.3K.
NovoCure made up 0.01% of Private Capital Group's portfolio in Q2 2022, its #1123 holding.
Private Capital Group first reported a position in NovoCure in Q4 2017 and has held it in 19 quarters since.
Private Capital Group's NovoCure position peaked at $174K in Q4 2020.
317 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.